Fragment Based Drug Discovery Market By Technique (X-ray Crystallography, NMR Spectroscopy, SPR, ITC, Others); By Service Type (Fragment Screening, Hit-to-Lead Optimization, Library Design, Custom Assays, Computational Modeling); By Therapeutic Area (Oncology, CNS Disorders, Infectious Diseases, Autoimmune, Rare Disorders); By End User (Pharmaceutical Companies, Biotech Firms, Academic & Research Institutes, CROs); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Fragment Based Drug Discovery Market will witness a strong CAGR of 14.5%, valued at USD 1.21 billion in 2024, and expected to reach USD 2.73 billion by 2030, according to Strategic Market Research.

 

Fragment based drug discovery (FBDD) has emerged as a highly efficient approach in the early phases of drug development. Instead of screening thousands of large compounds, FBDD starts small—literally. It identifies low-molecular-weight fragments that bind to biological targets and then optimizes them into potent drug candidates. Compared to traditional high-throughput screening, FBDD delivers higher hit rates, better ligand efficiency, and cleaner pharmacokinetic profiles. That's a big reason why it's no longer considered experimental—it's mainstream.

 

This methodology has gained strategic importance between 2024 and 2030, particularly as pharmaceutical pipelines get leaner and R&D costs climb. What’s driving FBDD forward is its clear alignment with precision medicine goals. By starting with small chemical fragments, researchers gain more control over the shape, flexibility, and selectivity of the final molecule. That’s not just a scientific win—it’s a commercial one, especially for complex diseases like cancer and neurological disorders.

 

Key stakeholders in this space include pharmaceutical giants, biotech innovators, academic drug discovery centers, contract research organizations (CROs), and technology providers building fragment libraries or NMR/X-ray platforms. These players are under increasing pressure to accelerate time-to-hit and reduce development waste. FBDD fits the bill—it shortens the cycle between hit identification and lead optimization. That’s gold in an industry obsessed with timelines.

 

Meanwhile, regulators like the FDA and EMA are giving green lights to fragment-derived drugs, validating the platform's credibility. Over a dozen drugs approved or in advanced trials were born through FBDD—ranging from BRAF inhibitors in oncology to protein–protein interaction disruptors for rare diseases.

 

Also worth noting: venture capital is paying attention. Investment in FBDD-focused biotech startups has picked up post-2022, with a handful of European and North American firms securing Series A and B rounds based purely on their fragment platforms. Some are even integrating AI into fragment optimization, pushing the boundaries of what’s possible at atomic resolution.

 

In a market where failure is expensive, FBDD isn’t just a cost-cutter—it’s a strategic hedge. It gives drug developers an option to pivot earlier, fail smarter, and scale what works. That makes this market one of the most methodologically innovative in modern drug discovery.

 

Market Segmentation And Forecast Scope

The fragment based drug discovery market can be segmented across several dimensions—each one reflecting how the drug development ecosystem integrates this method across therapeutic targets, research models, and enabling technologies. Here's how the segmentation logically unfolds:

By Technique

• X-ray Crystallography: Still the workhorse of structural-based FBDD, enabling direct visualization of fragment binding at atomic resolution. Most large pharma and well-funded CROs rely on this technique for hit validation and lead optimization.

• NMR Spectroscopy: Rapidly growing due to its ability to detect weak interactions in solution—a key advantage in the early fragment screening stage. Ideal for proteins that resist crystallization.

• Surface Plasmon Resonance (SPR): Often used post-screening to confirm hits and study binding kinetics. Especially relevant in immunology, oncology, and protein–protein interaction projects.

• Isothermal Titration Calorimetry (ITC): Valued for its quantitative binding affinity data, though less scalable. Used selectively in academic and advanced biophysics programs.

• Other Biophysical Techniques: Includes differential scanning fluorimetry (DSF), microscale thermophoresis (MST), and mass spectrometry-based screening, mostly applied in niche or exploratory contexts.

In 2024, X-ray crystallography holds the largest market share, but NMR spectroscopy is projected to grow at the fastest CAGR due to its expanding use in CNS, rare disease, and allosteric target programs.

 

By Service Type

• Fragment Screening: The foundational FBDD activity, accounting for the majority of outsourced demand. Includes wet-lab and virtual (in silico) screening using curated fragment libraries.

• Hit-to-Lead Optimization: Growing as biotechs and CROs bundle screening with medicinal chemistry and SAR campaigns to accelerate pipeline readiness.

• Fragment Library Design and Synthesis: Vendors are developing custom libraries for disease-specific, covalent, or macrocyclic fragments—becoming a critical value driver for niche targets.

• Custom Assay Development: Enables target-specific biophysical or biochemical assays to validate fragment hits. Especially useful for GPCRs, kinases, and hard-to-crystallize proteins.

• Computational Fragment Modeling: AI/ML-powered in silico modeling is gaining traction—used for hit expansion, scaffold hopping, and docking analysis. Popular with virtual-first startups and CNS-targeted campaigns.

While fragment screening remains the most in-demand service, the fastest-growing segment is computational modeling, thanks to integration with generative AI and quantum chemistry platforms.

 

By Therapeutic Area

• Oncology: The largest and most mature segment—over 40% of FBDD programs target cancer. High unmet need and protein–protein interactions make it an ideal testbed for fragment screening.

• Central Nervous System (CNS) Disorders: Expanding rapidly, particularly with AI-enhanced FBDD pipelines targeting neuroinflammation, Alzheimer’s-related kinases, and synaptic proteins.

• Infectious Diseases: Includes antiviral and antibacterial programs. Fragment-based screening is used to find selective inhibitors and overcome resistance.

• Autoimmune & Inflammatory Diseases: Growing interest in covalent fragments to modulate immune signaling pathways and reduce off-target toxicity.

• Rare and Genetic Disorders: FBDD's high selectivity and modular chemistry are well-suited for genetically defined targets—particularly for orphan drug development.

FBDD in oncology dominates by volume, but rare diseases and CNS disorders are fast-rising due to better target identification through genomics and phenotypic screening.

 

By End User

• Pharmaceutical Companies: Large pharma integrates FBDD into in-house discovery platforms—focusing on tough targets in oncology, immunology, and metabolic disease. Increasingly partnering with AI firms and library specialists.

• Biotechnology Firms: Lean startups and mid-stage biotechs use FBDD to differentiate their platforms—often outsourcing screening and integrating AI tools for hit expansion.

• Academic and Research Institutes: Drive methodological innovation, operate open-access fragment libraries, and partner with industry to advance first-in-class targets.

• Contract Research Organizations (CROs): Powering the democratization of FBDD through modular services. CROs offer fragment libraries, biophysical screening, medicinal chemistry, and cloud-enabled modeling platforms.

CROs and biotechs are the growth engines of FBDD outsourcing, while pharma is consolidating in-house capabilities and expanding through platform partnerships.

 

By Region

• North America: The global hub of FBDD activity, led by the U.S. Biotech clusters in Boston, San Diego, and Toronto are driving platform innovation. Access to AI talent, capital, and structural biology infrastructure is unmatched.

• Europe: Strong academic ecosystems (UK, Germany, France, Switzerland) are feeding commercial CROs and startups. EU-backed funding supports translational programs, especially in oncology and anti-infectives.

• Asia Pacific: The fastest-growing region. China and South Korea are investing in local CRO infrastructure and fragment libraries. Japan remains strong in CNS and crystallography-heavy discovery programs.

• Latin America: Still in early adoption, but showing research momentum in Brazil and Argentina. Fragment-derived drugs in global trials are increasing regional awareness and infrastructure needs.

• Middle East & Africa: Nascent stage with scattered pilot initiatives. However, biotechnology parks in the UAE and Saudi Arabia are exploring strategic collaborations in early discovery.

In 2024, North America and Europe together account for over 70% of the market. Asia Pacific is expected to contribute the largest absolute growth between 2024 and 2030, as local biopharma pipelines mature.

 

Scope Note

This segmentation isn’t just scientific—it’s commercial. Vendors are beginning to specialize across one or more of these layers. Some build out fragment libraries only. Others focus on custom NMR-based workflows. A few offer AI-enhanced optimization for CNS targets. This modularity is what’s making the market dynamic.

 

Market Trends And Innovation Landscape

Fragment based drug discovery has moved far beyond being a niche technique. Between 2024 and 2030, it’s evolving into a hybrid discipline that blends structural biology, AI, and bespoke chemistry—all with the goal of hitting tough targets faster. What’s fueling this shift? A mix of smarter tools, better data, and rising demand for novel chemical space. Let’s break down the trends shaping this market.

The AI–FBDD Convergence Is Real

AI in drug discovery isn’t new—but in FBDD, it’s getting more precise. Several startups are now training deep learning models on fragment–target interaction data, enabling faster hit validation and scaffold hopping. These tools are especially effective when fragment binding produces weak signals—something traditional methods often miss.

One UK-based platform is combining AI with biophysical input to predict not just where a fragment binds—but how it can evolve structurally into a druggable molecule. That’s a game changer for first-in-class therapies.

Also, generative models are being used to design virtual fragment libraries tailored to GPCRs, ion channels, or even viral proteins. This reduces the time needed to synthesize and physically screen large fragment sets.

 

Covalent and Macrocyclic Fragments Are Gaining Momentum

There’s growing interest in covalent fragment screening—where small molecules form irreversible bonds with amino acid side chains. These fragments often yield higher ligand efficiency and better selectivity, especially for enzymes and proteases. Oncology-focused programs are leading this trend, but neurodegeneration is close behind.

Macrocyclic fragments are another area to watch. While harder to design and synthesize, they offer excellent cell permeability and conformational rigidity—making them ideal for intracellular targets.

 

Miniaturization of Screening Technologies

Several biophysics vendors are racing to miniaturize fragment screening systems. We’re seeing next-gen NMR platforms designed for benchtop use, microfluidics-based SPR assays that cut down reagent costs, and AI-driven docking software that runs on cloud-based workstations.

These tools are enabling smaller biotech firms—and even some academic labs—to run sophisticated FBDD campaigns without multimillion-dollar infrastructure.

This democratization of fragment screening could drastically widen the pool of discovery programs across disease areas, geographies, and funding levels.

 

Integrated FBDD Platforms Are Becoming the Norm

In the past, fragment screening, optimization, and validation happened in silos. Not anymore. New entrants are building full-stack FBDD platforms—integrating everything from fragment design and in silico docking to co-crystallization and lead optimization under one roof. These companies are positioning themselves as discovery engines, not just service providers.

One biotech out of the U.S. raised a Series B in 2024 to expand its AI-integrated FBDD engine for kinase inhibitors—offering pharma partners faster routes to IND-stage candidates.

 

M&A and Strategic Partnerships Are Heating Up

Several mid-sized pharma firms, especially those with weak pipelines in neuro and oncology, are acquiring or partnering with FBDD specialists. These deals typically revolve around platform access, library licenses, or joint IP generation.

Also, big CROs are rolling up boutique fragment-screening shops to expand their discovery services footprint.

Expect more alliances between AI startups and FBDD service providers, aiming to create end-to-end discovery ecosystems tailored to specific therapeutic areas.

 

Push Into Undruggable Targets

Perhaps the most exciting trend is the application of FBDD in historically undruggable proteins—transcription factors, scaffolding proteins, or allosteric sites. Fragment libraries are being customized for these targets with unique 3D scaffolds and covalent tethers.

Some efforts are also exploring FBDD for RNA-binding small molecules—a frontier area with huge implications for antivirals and rare disease treatments.

 

Bottom line: the innovation pipeline in FBDD is exploding—not just with better tools, but with smarter workflows. It’s not about screening more. It’s about designing fragments that matter, and scaling up what works with unprecedented speed.

 

Competitive Intelligence And Benchmarking

The fragment based drug discovery market is structured around a dynamic mix of platform biotech firms, large pharmaceutical companies, academic collaborators, and CROs with specialized biophysical capabilities. Between 2024 and 2030, the competition is shifting from generic screening services to differentiated platforms that can optimize fragments quickly and reliably—especially for undruggable targets.

Here’s how the competitive field is shaping up:

Astex Pharmaceuticals

One of the earliest champions of FBDD, Astex continues to lead with its Pyramid platform, which integrates biophysical screening and structure-based design. Now operating under Otsuka Pharmaceutical, Astex is focused on oncology and CNS indications. What sets it apart is its emphasis on internal pipeline development—multiple molecules born from its FBDD platform are now in mid- to late-stage clinical trials.

Astex's credibility is helping de-risk FBDD across the industry, especially for companies looking to license rather than build.

 

Evotec

A major European force in outsourced drug discovery, Evotec offers full-suite FBDD services—from fragment screening to lead optimization. Its strength lies in its structural biology core, which includes one of the largest fragment libraries in the industry. Evotec is also expanding its AI and machine learning capabilities to support fragment prioritization.

Through strategic partnerships with pharma firms in immuno-oncology and inflammation, Evotec is leveraging FBDD to power high-value target discovery.

 

WuXi AppTec

This China-based giant has built a strong FBDD arm within its integrated drug discovery services. WuXi offers fragment-based screening using SPR, NMR, and X-ray crystallography—targeting global clients across the U.S., Europe, and Asia. Its differentiator? Speed and scalability, particularly for small to mid-sized biotech firms that need rapid turnaround on screening and SAR campaigns.

WuXi is also working on cloud-connected fragment libraries that allow remote clients to select screening panels virtually—an emerging business model in globalized R&D.

 

Domainex

A UK-based discovery CRO with a strong focus on FBDD, Domainex is known for its in-house library of over 1,500 chemically diverse fragments. It offers a streamlined workflow integrating thermal shift assays, SPR, and X-ray crystallography. The company is particularly strong in epigenetic target programs, having collaborated with academic institutions and pharma clients across Europe.

Its compact team and academic roots allow for highly customized FBDD campaigns—especially attractive to biotech startups in early funding stages.

 

Vernalis Research

Spun out from the former Vernalis plc, this UK-headquartered company has specialized expertise in NMR-based fragment screening. It’s one of the few CROs offering advanced NMR fragment screening as a core service, targeting clients in oncology, antibacterials, and CNS. Vernalis Research is also expanding into covalent fragment campaigns—an area of growing interest.

Its NMR-first approach is ideal for targets where crystallographic data is difficult to obtain—giving it an edge in structurally challenging projects.

 

Standouts from Academia

Academic labs such as the Structural Genomics Consortium and University of Cambridge’s Department of Chemistry remain influential in FBDD development. These centers not only contribute open-access fragment libraries but also collaborate on structural biology protocols that often become industry standards.

Several biotech startups have spun out of these programs, adding to the diversity of innovation in the field.

 

Competitive Outlook

The core competition isn’t about who has the biggest fragment library anymore. It’s about who can connect fragment screening with fast optimization, AI prediction, and pathway-aware target selection. Players that can build these links internally—or through strategic alliances—will lead the next phase of market growth.

Differentiation is increasingly coming from disease-specific platforms, proprietary libraries (e.g., covalent or macrocyclic fragments), and integration with AI/ML tools. That’s changing how deals are made—partners aren’t just buying screening services. They want access to IP, joint discovery, and co-ownership of optimized leads.

 

Regional Landscape And Adoption Outlook

The adoption of fragment based drug discovery varies sharply by region—driven by factors like structural biology infrastructure, government funding for life sciences, biopharma innovation density, and availability of skilled researchers. Between 2024 and 2030, geographic expansion in the FBDD market is expected to intensify, particularly as emerging biotech ecosystems adopt leaner, cost-effective discovery methods.

North America

North America leads the global FBDD market, thanks to a combination of mature pharmaceutical R&D, early academic innovation, and a deep network of contract research partners. The United States, in particular, has been instrumental in developing and scaling fragment-based methods, largely through NIH-funded programs and industry–academia collaboration.

The region also benefits from strong integration between AI startups and structural biology labs—accelerating the fusion of computational and physical screening methods. Companies in Boston, San Diego, and Toronto are increasingly bundling FBDD services into broader discovery platforms, particularly for oncology and rare diseases.

U.S.-based biotech firms are now raising capital based on FBDD pipelines alone, indicating strong investor confidence in the approach.

 

Europe

Europe remains a close second in terms of FBDD innovation. The United Kingdom, Germany, France, and the Netherlands have produced a high density of CROs and academic centers focused on structure-based drug design. Public–private initiatives—such as EU-backed drug discovery hubs—have helped make FBDD accessible to smaller companies.

There’s also an uptick in covalent fragment discovery across Germany and Switzerland, especially targeting antimicrobial resistance and novel kinase inhibitors. The region is witnessing growing licensing activity between pharma and boutique FBDD firms.

The UK’s emphasis on pre-competitive open data sharing in structural biology is also feeding faster discovery cycles across therapeutic areas.

 

Asia Pacific

Asia Pacific is the fastest-growing region for fragment based drug discovery. While the region historically lagged behind in structural biology capacity, that’s changing quickly. China, South Korea, and Japan are investing heavily in biophysical screening tools and local fragment libraries.

In China, domestic CROs have expanded their capabilities rapidly, offering low-cost, high-throughput screening for local and global biotech clients. South Korea’s biotech incubators are pushing fragment campaigns in neurology and immune-oncology, often in partnership with U.S. firms.

APAC’s rising adoption is being fueled by a dual strategy: importing know-how through licensing deals and building indigenous capabilities at speed.

 

Latin America

Fragment based approaches are still in the early adoption phase in Latin America. Brazil and Argentina have shown interest through academic collaborations and limited-scale CRO investments, but broader structural biology capacity is lacking. However, the region is being included more frequently in global clinical trials involving fragment-derived drugs—creating some downstream demand for FBDD services.

There’s an emerging opportunity for technology transfer and training collaborations in the region, especially in university-driven research hubs.

 

Middle East & Africa

The Middle East & Africa remains a nascent market for FBDD. Some investment is emerging from Gulf states in biotechnology parks, but currently, the region lacks the core infrastructure to support full-fledged fragment-based discovery pipelines. However, partnerships with European and Asian CROs may bridge the gap in the short term.

Longer term, regional interest may rise if local pharma companies begin outsourcing fragment screening to accelerate generics-to-innovation transitions.

 

Regional Summary

Each region brings a distinct adoption profile to the FBDD space. North America and Europe dominate in terms of innovation and commercialization. Asia Pacific is rapidly building scale, while Latin America and the Middle East are at early stages but not without long-term potential.

This uneven adoption curve is shaping how companies approach geographic expansion. Rather than selling FBDD as a monolithic platform, vendors are adapting their services to fit local infrastructure, regulatory comfort, and therapeutic focus.

 

End-User Dynamics And Use Case

Fragment based drug discovery isn’t just a method—it’s a strategic tool. Different types of end users are integrating FBDD into their workflows based on varying goals, resource levels, and therapeutic focus. Between 2024 and 2030, the user landscape is becoming more segmented, as small biotech firms, large pharma, and academic labs adopt FBDD for very different reasons.

Pharmaceutical Companies

For large pharmaceutical companies, FBDD is used to reduce the risk and cost associated with early-stage development. These organizations typically internalize the entire FBDD pipeline—from fragment screening to lead optimization—within their discovery units. They invest in building large, diverse fragment libraries and often pair them with proprietary computational tools.

FBDD is increasingly viewed by big pharma as a way to address targets that have failed with traditional high-throughput screening. It’s especially attractive in oncology, metabolic disease, and CNS disorders, where target selectivity is essential.

Pharma giants are now licensing fragment libraries from smaller firms or academia to expand the diversity of their hit space—without bloating their internal resources.

 

Biotechnology Firms

Biotechs, especially those in seed or Series A stages, are leaning on FBDD to establish competitive differentiation with lean teams and limited infrastructure. These companies rarely own full libraries or biophysical screening platforms—instead, they form partnerships with CROs or academic centers to access these tools.

FBDD enables them to move quickly from target validation to lead series, often with a tighter focus on novel modalities like covalent inhibitors or protein–protein interaction disruptors. For some, FBDD is central to their entire platform pitch to investors.

What used to require multimillion-dollar investment in equipment and personnel is now being done in modular workflows—outsourced, on demand, and fast.

 

Contract Research Organizations (CROs)

CROs are the backbone of FBDD access for small to mid-sized innovators. These service providers specialize in fragment screening, structure determination, and medicinal chemistry. They often differentiate based on their proprietary libraries, turnaround speed, or integration with AI prediction tools.

Larger CROs are offering FBDD as part of end-to-end discovery services, creating a one-stop shop for hit identification, optimization, and preclinical validation.

CROs are also adapting their offerings by region—providing low-cost services in Asia Pacific and premium, niche fragment campaigns in North America and Europe.

 

Academic and Research Institutes

Academic labs remain essential for both FBDD innovation and execution. Many host fragment libraries, operate high-field NMR or crystallography facilities, and develop the screening protocols later adopted by CROs or pharma. Their contributions are particularly strong in early-stage screening and proof-of-concept projects.

Increasingly, academic groups are entering into long-term alliances with industry players, enabling commercial use of their libraries and facilities under sponsored research agreements.

Some of the most innovative fragment scaffolds in development today originated from academic labs with deep expertise in structural biology and medicinal chemistry.

 

Real-World Use Case

A good example of FBDD in action comes from a mid-sized biotech in South Korea targeting an Alzheimer’s-related kinase. The company, lacking in-house structural biology, partnered with a European CRO to conduct NMR-based screening against the kinase’s allosteric pocket. Within three months, the team had identified a high-affinity fragment with favorable CNS penetration predicted via in silico models.

Medicinal chemistry cycles turned the hit into a low-nanomolar lead, which is now entering IND-enabling studies. What made this work? A modular approach: outsourced library screening, AI-driven fragment expansion, and in-house ADMET testing—blending speed with selectivity.

This kind of workflow is becoming the norm. The value lies in flexibility, not ownership—and that’s redefining how different users approach FBDD.

 

Recent Developments + Opportunities & Restraints

Recent Developments (Last 2 Years)

• Astex Pharmaceuticals and Taiho Oncology expanded their oncology partnership in 2023 to co-develop multiple fragment-based kinase inhibitors, accelerating IND submissions for two candidates.

• WuXi AppTec launched a cloud-enabled fragment screening platform in 2024, allowing virtual access to their proprietary libraries and SPR/NMR-based analysis tools for remote biotech clients.

• Evotec acquired a U.S.-based AI startup in early 2024, integrating deep learning models into its FBDD workflow to improve fragment prioritization and SAR prediction.

• Domainex partnered with the University of Cambridge in 2023 to co-develop macrocyclic fragment libraries targeting GPCRs—one of the most challenging protein families for drug design.

• A German biotech secured €30 million in Series B funding in late 2024 to commercialize its covalent fragment screening platform, with early traction in antimicrobial and inflammation programs.

 

Opportunities

• AI-Powered Optimization:
  Integration of AI with FBDD workflows is unlocking faster hit-to-lead timelines and enabling deeper exploration of chemical space, especially for allosteric and non-classical targets.

• Emergence of Covalent and Macrocyclic Fragments:
  These fragment types are gaining traction for their ability to modulate previously undruggable proteins, opening new therapeutic frontiers in oncology, CNS, and infectious diseases.

• Fragment-Based Discovery in Rare Diseases:
  The method’s ability to fine-tune selectivity is ideal for genetically defined targets—offering commercial promise for biotechs focused on precision medicine in rare conditions.

 

Restraints

• High Cost of Infrastructure:
  Despite modular outsourcing models, full in-house FBDD capability remains capital intensive, especially with the need for advanced NMR, crystallography, and cheminformatics platforms.

• Shortage of Skilled Structural Biologists:
  The market faces a talent bottleneck. Many regions lack trained professionals with deep expertise in biophysical fragment screening and structural optimization—a constraint on scaling FBDD.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 1.21 Billion
Revenue Forecast in 2030	USD 2.73 Billion
Overall Growth Rate	CAGR of 14.5% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Technique, By Service Type, By Therapeutic Area, By End User, By Geography
By Technique	X-ray Crystallography, NMR Spectroscopy, SPR, ITC, Others
By Service Type	Fragment Screening, Hit-to-Lead Optimization, Library Design, Custom Assays, Computational Modeling
By Therapeutic Area	Oncology, CNS Disorders, Infectious Diseases, Autoimmune, Rare Disorders
By End User	Pharmaceutical Companies, Biotech Firms, Academic & Research Institutes, CROs
By Region	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, Germany, U.K., France, China, India, Japan, South Korea, Brazil, etc.
Market Drivers	- AI-integrated fragment optimization - Expansion of covalent and macrocyclic fragment platforms - Demand for targeted therapies in oncology and rare diseases
Customization Option	Available upon request